In Vitro Investigations on Optimizing and Nebulization of IVT-mRNA Formulations for Potential Pulmonary-Based Alpha-1-Antitrypsin Deficiency Treatment
Open Access
- 17 August 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (8) , 1281
Abstract
In vitro-transcribed (IVT) mRNA has come into focus in recent years as a potential therapeutic approach for the treatment of genetic diseases. The nebulized formulations of IVT-mRNA-encoding alpha-1-antitrypsin (A1AT-mRNA) would be a highly acceptable and tolerable remedy for the protein replacement therapy for alpha-1-antitrypsin deficiency in the future. Here we show that lipoplexes containing A1AT-mRNA prepared in optimum conditions could successfully transfect human bronchial epithelial cells without significant toxicity. A reduction in transfection efficiency was observed for aerosolized lipoplexes that can be partially overcome by increasing the initial number of components. A1AT produced from cells transfected by nebulized A1AT-mRNA lipoplexes is functional and could successfully inhibit the enzyme activity of trypsin as well as elastase. Our data indicate that aerosolization of A1AT-mRNA therapy constitutes a potentially powerful means to transfect airway epithelial cells with the purpose of producing functional A1AT, while bringing along the unique advantages of IVT-mRNA.Keywords
All Related Versions
Funding Information
- Chongqing Talents Award (CQYC202005027)
- Bayerisches Staatsministerium für Wirtschaft und Medien, Energie und Technologie (41-6561a/25/1-FLU-1707-0004)
This publication has 52 references indexed in Scilit:
- Alpha-1 Antitrypsin Augmentation TherapyCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2013
- Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responsesRespiratory Research, 2013
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNANucleic Acids Research, 2011
- mRNA as gene therapeutic: How to control protein expressionJournal of Controlled Release, 2011
- Expression of therapeutic proteins after delivery of chemically modified mRNA in miceNature Biotechnology, 2011
- mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriersJournal of Controlled Release, 2010
- Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapyClinical Immunology, 2010
- Breaking up the correlation between efficacy and toxicity for nonviral gene deliveryProceedings of the National Academy of Sciences, 2007
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- Molecular basis of alpha-1-antitrypsin deficiencyThe American Journal of Medicine, 1988